A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer

被引：1
|
作者：
Gill, Harpaul S. [1 ]
Ramalingam, Suresh S. [1 ]
机构：
[1] Emory Univ, Sch Med, Dept Hematol & Oncol, Winship Canc Inst, 1365 Clifton Rd NE,Bldg C,Suite 4014, Atlanta, GA 30322 USA
来源：
CANCER | 2019年 / 125卷 / 13期
关键词：
durvalumab; immune checkpoint inhibition; NSCLC; PACIFIC trial; stage III NSCLC; RANDOMIZED PHASE-III; RADIATION-THERAPY; CONCURRENT CHEMORADIOTHERAPY; SEQUENTIAL CHEMORADIOTHERAPY; CONSOLIDATION DOCETAXEL; THORACIC RADIOTHERAPY; TRIAL; CHEMOTHERAPY; COMBINATION; CARBOPLATIN;
D O I：
10.1002/cncr.31996
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Overall survival data from the PACIFIC trial have reaffirmed earlier US Food and Drug Administration approval of durvalumab in patients with stage III non-small cell lung cancer. In the current commentary, the authors provide a brief historical perspective on stage III disease as well as a further analysis of the strengths and weaknesses of the trial.
引用
收藏
页码：2148 / 2153
页数：6
相关论文
共 50 条
  • [1] Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer
    Ahn, Myung-Ju
    JOURNAL OF THORACIC DISEASE, 2018, 10 (03) : 1205 - 1206
  • [2] Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer
    Kerner, Gerald S. M. A.
    van Dullemen, Leon F. A.
    Wiegman, Erwin M.
    Widder, Joachim
    Blokzijl, Edwin
    Driever, Ellen M.
    van Putten, John W. G.
    Liesker, Jeroen J. W.
    Renkema, Tineke E. J.
    Pieterman, Remge M.
    Mertens, Marc J. F.
    Hiltermann, Thijo J. N.
    Groen, Harry J. M.
    RADIATION ONCOLOGY, 2014, 9
  • [3] The Optimal Chemotherapy for Stage III Non-Small Cell Lung Cancer Patients
    Gadgeel, Shirish M.
    CURRENT ONCOLOGY REPORTS, 2011, 13 (04) : 272 - 279
  • [4] Management of stage III non-small cell lung cancer
    Tabchi, Samer
    Kassouf, Elie
    El Rassy, Elie
    Kourie, Hampig Raphael
    Martin, Jocelyne
    Campeau, Marie-Pierre
    Tehfe, Mustapha
    Blais, Normand
    SEMINARS IN ONCOLOGY, 2017, 44 (03) : 163 - 177
  • [5] Ineligibility for the PACIFIC trial in unresectable stage III non-small cell lung cancer patients
    Hosoya, Kazutaka
    Fujimoto, Daichi
    Kawachi, Hayato
    Sato, Yuki
    Kogo, Mariko
    Nagata, Kazuma
    Nakagawa, Atsushi
    Tachikawa, Ryo
    Hiraoka, Shinya
    Kokubo, Masaki
    Tomii, Keisuke
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 275 - 280
  • [6] Optimizing current standard of care therapy for stage III non-small cell lung cancer
    Verma, Vivek
    Lin, Steven H.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (05) : 2033 - 2039
  • [7] Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer
    Skrzypski, Marcin
    Jassem, Jacek
    CANCER TREATMENT REVIEWS, 2018, 66 : 114 - 121
  • [8] Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: A systematic review of completed and ongoing studies
    Choy, Hak
    Gerber, David E.
    Bradley, Jeffrey D.
    Iyengar, Puneeth
    Monberg, Matthew
    Treat, Joseph
    Govindan, Ramaswamy
    Koustensis, Andrew
    Barker, Scott
    Obasaju, Coleman
    LUNG CANCER, 2015, 87 (03) : 232 - 240
  • [9] Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
    Mooradian, Meghan J.
    Cai, Ling
    Wang, Alice
    Qiao, Yao
    Chander, Pratibha
    Whitaker, Ryan M.
    JAMA NETWORK OPEN, 2024, 7 (04) : e247542
  • [10] Treatment patterns and long-term survival outcomes for patients with stage III non-small cell lung cancer: A retrospective study
    Kumari, Seema
    Karikios, Deme
    Yeghiaian-Alvandi, Roland
    Flynn, Peter
    Morgan, Lucy
    Kay, Lisa
    Ding, Pei
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 (01) : 25 - 31
12345